<DOC>
	<DOCNO>NCT02514213</DOCNO>
	<brief_summary>This phase I , open-label trial evaluate safety immunogenicity INO 5150 alone combination INO-9012 deliver intramuscularly ( IM ) follow electroporation ( EP ) men biochemically relapse prostate cancer .</brief_summary>
	<brief_title>Trial Evaluate Safety Immunogenicity INO-5150 Alone With INO-9012 Men With Prostate Cancer</brief_title>
	<detailed_description>Phase I , open label study INO-5150 ( DNA plasmid encode prostate specific antigen ( PSA ) prostate specific membrane antigen ( PSMA ) ) alone co-administered INO-9012 ( IL-12 plasmid ) deliver intramuscularly follow EP use CELLECTRA®-5P device adult male biochemically relapsed prostate cancer follow definitive local therapy ( e.g . prostatectomy , external beam radiation , brachytherapy ) . Four injection administer approximately 60 eligible subject consent participate study . Subjects monitor safety immunogenicity Week 72 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Men age 18 90 year histologic diagnosis prostate cancer ; 2. c. Biochemical recurrence follow local therapy , either surgery radiation . Rising PSA define : After definitive surgery , e.g . After radical prostatectomy , two PSA measurement ≥ 1.0 ng/mL least one week apart ; After cryosurgery , two PSA measurement ≥ 2.0 ng/mL least one week apart ; Other definitive surgical procedure may permissible upon approval medical monitor OR After radiation therapy ( e.g. , external beam radiation , brachytherapy , salvage/adjuvant radiation therapy surgery ) , two post radiation PSA measurement level nadir plus 2.0 ng/mL least one week apart . ; 3 . Serum testosterone level : ) Subjects history androgen deprivation therapy : A single measurement great 150 ng/dL 5.2 nmol/L within 3 month enrollment ii ) Subjects history androgen deprivation therapy ( either adjuvant biochemical relapse set ) : The two recent measurement serum testosterone prior enrollment must fulfill follow criterion : Both measurement great 150 ng/dL 5.2 nmol/L ; The two measurement space least 14 day apart ; Both must measure within 3 month enrollment ; 4 . Normal electro cardio gram ( ECG ) ECG clinically significant finding ; 5 . Adequate bone marrow , hepatic , renal function test within 30 day prior enrollment : CBC ( except platelet hemoglobin ) , serum chemistry , liver panel , CPK value ≤ Grade 1 abnormality define CTCAE v 4.03 date June 14 , 2010 Platelets ≥ 75,000 /mL ; Hemoglobin ≥ 9.0 g/dL ; 6 . No desire plan father new child study and/or prior vasectomy 1 . PSA double time ( PSADT ) ≤ 3 month , use 2 PSA value least 4 week apart , calculate accord Memorial SloanKettering Cancer Center nomogram ( http : //www.mskcc.org/nomograms/prostate/psadoublingtime ) ; 2 . Clinical radiologic evidence distant metastatic disease small volume ( &lt; 1.5 cm ) node , test within 12 month enrollment ; 3 . Receipt investigational therapy clinical trial set within 30 day enrollment ; 4 . Any preexcitation syndrome , e.g. , WolffParkinsonWhite syndrome ; 5 . Prior major surgery radiation therapy within 4 week enrollment ; 6 . Any prior chemotherapy , except shortcourse neoadjuvant adjuvant chemotherapy stop least 6 week prior Study enrollment ; 7 . Active AIDS / HIV infection , clinically uncontrolled immune deficiency disorder ; 8 . Clinically uncontrolled autoimmune disorder , transplant recipient depend immunosuppressive therapy , immunosuppressive condition include concurrent condition require immunosuppressive/immunomodulating agent ; 9 . Recipient blood product immunotherapy ( antiPD1 , antiPDL1 antiCTLA4 ) within 3 month enrollment ;</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>PSA</keyword>
</DOC>